Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-06

AUTHORS

Yoshitomo Kobori, Yasuhide Kitagawa, Atsushi Mizokami, Kazuto Komatsu, Mikio Namiki

ABSTRACT

BACKGROUND: Although the free-to-total prostate-specific antigen (PSA) ratio (f/t ratio) is low in prostate cancer, its usefulness in mass screening remains unclear. We examined the clinical usefulness of the f/t ratio for screening in a Japanese population. METHODS: Since 2000, we have performed PSA screening in Japanese men aged 55-69 years. From 2000 to 2002, patients with total PSA (tPSA) levels over 2.1 ng/ml were referred to the urological clinic for secondary screening, regardless of the f/t ratio. We analyzed both the tPSA level and the f/t ratio in prostate cancer patients, and since 2003, subjects with tPSA levels ranging from 2.1-10.0 ng/ml and f/t ratios higher than 0.22 have not been referred for secondary screening. Here, we report the results of tPSA screening, comparing findings in the two periods (2000-2002 and 2003-2005). RESULTS: Between 2000 and 2005, we performed the tPSA screening test in 27 730 men, and detected 214 cases of prostate cancer. Sixty patients (28.0%) showed tPSA levels between 2.1 and 4.0 g/ml. There were no differences in cancer detection rates between the two periods in the populations referred for an initial screening. However, the percentage of individuals referred for secondary screening decreased from 17.0% to 13.0% during the later period (P < 0.001). The cancer detection rate in all patients with biopsies rose from 13.5% in the earlier period to 22.7% in the later period for the group with tPSA between 2.1 and 10.0 ng/ml (P < 0.001). CONCLUSION: The f/t ratio may be a useful additional screening parameter for patients showing tPSA levels between 2.1 and 10.0 ng/ml on their initial screening examination. More... »

PAGES

229-232

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10147-007-0742-2

DOI

http://dx.doi.org/10.1007/s10147-007-0742-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1026539447

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18553232


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mass Screening", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Kanazawa University", 
          "id": "https://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, 920-8640, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kobori", 
        "givenName": "Yoshitomo", 
        "id": "sg:person.0617361370.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617361370.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kanazawa University", 
          "id": "https://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, 920-8640, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kitagawa", 
        "givenName": "Yasuhide", 
        "id": "sg:person.01361101243.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361101243.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kanazawa University", 
          "id": "https://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, 920-8640, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizokami", 
        "givenName": "Atsushi", 
        "id": "sg:person.0751723543.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751723543.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Fukui Red Cross Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415129.a", 
          "name": [
            "Department of Urology, Fukui Red Cross Hospital, Fukui, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komatsu", 
        "givenName": "Kazuto", 
        "id": "sg:person.014470331472.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014470331472.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Kanazawa University", 
          "id": "https://www.grid.ac/institutes/grid.9707.9", 
          "name": [
            "Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, 920-8640, Kanazawa, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Namiki", 
        "givenName": "Mikio", 
        "id": "sg:person.01204667775.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204667775.55"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejm198710083171501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004570779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.1997.03540420048028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010397157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa031918", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013014513"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0094-0143(05)70376-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014767971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0094-0143(05)70376-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014767971"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(05)66451-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015986636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1745-7262.2006.00155.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027060352", 
          "https://doi.org/10.1111/j.1745-7262.2006.00155.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(05)66519-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029322735"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1442-2042.2005.01056.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032114814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1442-2042.2005.01056.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032114814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa021659", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033436340"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0022-5347(01)66260-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047587056"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1442-2042.1999.00098.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050520919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1442-2042.1999.00098.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050520919"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2005.05800.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050522621"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-410x.2005.05800.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050522621"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl087", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051858254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.277.18.1452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054160915"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-06", 
    "datePublishedReg": "2008-06-01", 
    "description": "BACKGROUND: Although the free-to-total prostate-specific antigen (PSA) ratio (f/t ratio) is low in prostate cancer, its usefulness in mass screening remains unclear. We examined the clinical usefulness of the f/t ratio for screening in a Japanese population.\nMETHODS: Since 2000, we have performed PSA screening in Japanese men aged 55-69 years. From 2000 to 2002, patients with total PSA (tPSA) levels over 2.1 ng/ml were referred to the urological clinic for secondary screening, regardless of the f/t ratio. We analyzed both the tPSA level and the f/t ratio in prostate cancer patients, and since 2003, subjects with tPSA levels ranging from 2.1-10.0 ng/ml and f/t ratios higher than 0.22 have not been referred for secondary screening. Here, we report the results of tPSA screening, comparing findings in the two periods (2000-2002 and 2003-2005).\nRESULTS: Between 2000 and 2005, we performed the tPSA screening test in 27 730 men, and detected 214 cases of prostate cancer. Sixty patients (28.0%) showed tPSA levels between 2.1 and 4.0 g/ml. There were no differences in cancer detection rates between the two periods in the populations referred for an initial screening. However, the percentage of individuals referred for secondary screening decreased from 17.0% to 13.0% during the later period (P < 0.001). The cancer detection rate in all patients with biopsies rose from 13.5% in the earlier period to 22.7% in the later period for the group with tPSA between 2.1 and 10.0 ng/ml (P < 0.001).\nCONCLUSION: The f/t ratio may be a useful additional screening parameter for patients showing tPSA levels between 2.1 and 10.0 ng/ml on their initial screening examination.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10147-007-0742-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1312225", 
        "issn": [
          "1341-9625", 
          "1437-7772"
        ], 
        "name": "International Journal of Clinical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "13"
      }
    ], 
    "name": "Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1\u201310.0 ng/ml as a criterion", 
    "pagination": "229-232", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "7e6f786174d06b6ddeb69be71f36168281115d943d9c5c9ba6dea725e48b5d31"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18553232"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9616295"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10147-007-0742-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1026539447"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10147-007-0742-2", 
      "https://app.dimensions.ai/details/publication/pub.1026539447"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13104_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s10147-007-0742-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10147-007-0742-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10147-007-0742-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10147-007-0742-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10147-007-0742-2'


 

This table displays all metadata directly associated to this object as RDF triples.

175 TRIPLES      21 PREDICATES      51 URIs      29 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10147-007-0742-2 schema:about N1cb24cc30bfa4c4692d5e4afd40cb4bd
2 N811f29de392842e69c1e69bc0c8f0b17
3 Na6e3ded8279643518f7c9a08d394526c
4 Ne712badb6a274f85a0f075a1f9239eb8
5 Nf40ee4fecd0e4fdf8c0b8be2b3a68263
6 Nf64bb6a20cc34abebd98e315e748fcc8
7 Nf96846a6785a49bd96e9e1528a1bc10b
8 Nfc2ebd5dd374416c8734fb7e5e962b69
9 anzsrc-for:11
10 anzsrc-for:1117
11 schema:author N72128a6e082143358beb6a7f3feb0586
12 schema:citation sg:pub.10.1111/j.1745-7262.2006.00155.x
13 https://doi.org/10.1001/jama.1997.03540420048028
14 https://doi.org/10.1001/jama.277.18.1452
15 https://doi.org/10.1016/s0022-5347(01)66260-8
16 https://doi.org/10.1016/s0022-5347(05)66451-8
17 https://doi.org/10.1016/s0022-5347(05)66519-6
18 https://doi.org/10.1016/s0094-0143(05)70376-1
19 https://doi.org/10.1046/j.1442-2042.1999.00098.x
20 https://doi.org/10.1056/nejm198710083171501
21 https://doi.org/10.1056/nejmoa021659
22 https://doi.org/10.1056/nejmoa031918
23 https://doi.org/10.1093/annonc/mdl087
24 https://doi.org/10.1111/j.1442-2042.2005.01056.x
25 https://doi.org/10.1111/j.1464-410x.2005.05800.x
26 schema:datePublished 2008-06
27 schema:datePublishedReg 2008-06-01
28 schema:description BACKGROUND: Although the free-to-total prostate-specific antigen (PSA) ratio (f/t ratio) is low in prostate cancer, its usefulness in mass screening remains unclear. We examined the clinical usefulness of the f/t ratio for screening in a Japanese population. METHODS: Since 2000, we have performed PSA screening in Japanese men aged 55-69 years. From 2000 to 2002, patients with total PSA (tPSA) levels over 2.1 ng/ml were referred to the urological clinic for secondary screening, regardless of the f/t ratio. We analyzed both the tPSA level and the f/t ratio in prostate cancer patients, and since 2003, subjects with tPSA levels ranging from 2.1-10.0 ng/ml and f/t ratios higher than 0.22 have not been referred for secondary screening. Here, we report the results of tPSA screening, comparing findings in the two periods (2000-2002 and 2003-2005). RESULTS: Between 2000 and 2005, we performed the tPSA screening test in 27 730 men, and detected 214 cases of prostate cancer. Sixty patients (28.0%) showed tPSA levels between 2.1 and 4.0 g/ml. There were no differences in cancer detection rates between the two periods in the populations referred for an initial screening. However, the percentage of individuals referred for secondary screening decreased from 17.0% to 13.0% during the later period (P < 0.001). The cancer detection rate in all patients with biopsies rose from 13.5% in the earlier period to 22.7% in the later period for the group with tPSA between 2.1 and 10.0 ng/ml (P < 0.001). CONCLUSION: The f/t ratio may be a useful additional screening parameter for patients showing tPSA levels between 2.1 and 10.0 ng/ml on their initial screening examination.
29 schema:genre research_article
30 schema:inLanguage en
31 schema:isAccessibleForFree false
32 schema:isPartOf Nc0a1b2eba5d2430c846cd3d03408638a
33 Nf038859f59654e338e76fb19d993e5ef
34 sg:journal.1312225
35 schema:name Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1–10.0 ng/ml as a criterion
36 schema:pagination 229-232
37 schema:productId N78a1016c5bbd4e6f80d94dc927b7d81c
38 N7b641a924a094634b6720e52745782c4
39 Na124874ac1374500b14d2b62df61c49e
40 Nd31559e8880d4f54bc6eccecc5b1cf96
41 Nd3dac69a19a64702b955f6b04f6f3229
42 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026539447
43 https://doi.org/10.1007/s10147-007-0742-2
44 schema:sdDatePublished 2019-04-11T14:33
45 schema:sdLicense https://scigraph.springernature.com/explorer/license/
46 schema:sdPublisher N59b6b279ba664d58940ab481a65bebb6
47 schema:url http://link.springer.com/10.1007/s10147-007-0742-2
48 sgo:license sg:explorer/license/
49 sgo:sdDataset articles
50 rdf:type schema:ScholarlyArticle
51 N1cb24cc30bfa4c4692d5e4afd40cb4bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
52 schema:name Prostate-Specific Antigen
53 rdf:type schema:DefinedTerm
54 N3703edd9e76f4ca8be738c59fe368a3a rdf:first sg:person.0751723543.89
55 rdf:rest N4799127b1cc04439bc786a66f1157f8f
56 N419d48a2c67a4dafb8e32be0a21364df rdf:first sg:person.01204667775.55
57 rdf:rest rdf:nil
58 N43ad6891b45e4b7c8df437699ab12585 rdf:first sg:person.01361101243.27
59 rdf:rest N3703edd9e76f4ca8be738c59fe368a3a
60 N4799127b1cc04439bc786a66f1157f8f rdf:first sg:person.014470331472.15
61 rdf:rest N419d48a2c67a4dafb8e32be0a21364df
62 N59b6b279ba664d58940ab481a65bebb6 schema:name Springer Nature - SN SciGraph project
63 rdf:type schema:Organization
64 N72128a6e082143358beb6a7f3feb0586 rdf:first sg:person.0617361370.06
65 rdf:rest N43ad6891b45e4b7c8df437699ab12585
66 N78a1016c5bbd4e6f80d94dc927b7d81c schema:name readcube_id
67 schema:value 7e6f786174d06b6ddeb69be71f36168281115d943d9c5c9ba6dea725e48b5d31
68 rdf:type schema:PropertyValue
69 N7b641a924a094634b6720e52745782c4 schema:name nlm_unique_id
70 schema:value 9616295
71 rdf:type schema:PropertyValue
72 N811f29de392842e69c1e69bc0c8f0b17 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Prostatic Neoplasms
74 rdf:type schema:DefinedTerm
75 Na124874ac1374500b14d2b62df61c49e schema:name pubmed_id
76 schema:value 18553232
77 rdf:type schema:PropertyValue
78 Na6e3ded8279643518f7c9a08d394526c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Japan
80 rdf:type schema:DefinedTerm
81 Nc0a1b2eba5d2430c846cd3d03408638a schema:volumeNumber 13
82 rdf:type schema:PublicationVolume
83 Nd31559e8880d4f54bc6eccecc5b1cf96 schema:name dimensions_id
84 schema:value pub.1026539447
85 rdf:type schema:PropertyValue
86 Nd3dac69a19a64702b955f6b04f6f3229 schema:name doi
87 schema:value 10.1007/s10147-007-0742-2
88 rdf:type schema:PropertyValue
89 Ne712badb6a274f85a0f075a1f9239eb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Humans
91 rdf:type schema:DefinedTerm
92 Nf038859f59654e338e76fb19d993e5ef schema:issueNumber 3
93 rdf:type schema:PublicationIssue
94 Nf40ee4fecd0e4fdf8c0b8be2b3a68263 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Male
96 rdf:type schema:DefinedTerm
97 Nf64bb6a20cc34abebd98e315e748fcc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Middle Aged
99 rdf:type schema:DefinedTerm
100 Nf96846a6785a49bd96e9e1528a1bc10b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Mass Screening
102 rdf:type schema:DefinedTerm
103 Nfc2ebd5dd374416c8734fb7e5e962b69 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Aged
105 rdf:type schema:DefinedTerm
106 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
107 schema:name Medical and Health Sciences
108 rdf:type schema:DefinedTerm
109 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
110 schema:name Public Health and Health Services
111 rdf:type schema:DefinedTerm
112 sg:journal.1312225 schema:issn 1341-9625
113 1437-7772
114 schema:name International Journal of Clinical Oncology
115 rdf:type schema:Periodical
116 sg:person.01204667775.55 schema:affiliation https://www.grid.ac/institutes/grid.9707.9
117 schema:familyName Namiki
118 schema:givenName Mikio
119 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204667775.55
120 rdf:type schema:Person
121 sg:person.01361101243.27 schema:affiliation https://www.grid.ac/institutes/grid.9707.9
122 schema:familyName Kitagawa
123 schema:givenName Yasuhide
124 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01361101243.27
125 rdf:type schema:Person
126 sg:person.014470331472.15 schema:affiliation https://www.grid.ac/institutes/grid.415129.a
127 schema:familyName Komatsu
128 schema:givenName Kazuto
129 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014470331472.15
130 rdf:type schema:Person
131 sg:person.0617361370.06 schema:affiliation https://www.grid.ac/institutes/grid.9707.9
132 schema:familyName Kobori
133 schema:givenName Yoshitomo
134 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617361370.06
135 rdf:type schema:Person
136 sg:person.0751723543.89 schema:affiliation https://www.grid.ac/institutes/grid.9707.9
137 schema:familyName Mizokami
138 schema:givenName Atsushi
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751723543.89
140 rdf:type schema:Person
141 sg:pub.10.1111/j.1745-7262.2006.00155.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027060352
142 https://doi.org/10.1111/j.1745-7262.2006.00155.x
143 rdf:type schema:CreativeWork
144 https://doi.org/10.1001/jama.1997.03540420048028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010397157
145 rdf:type schema:CreativeWork
146 https://doi.org/10.1001/jama.277.18.1452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054160915
147 rdf:type schema:CreativeWork
148 https://doi.org/10.1016/s0022-5347(01)66260-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047587056
149 rdf:type schema:CreativeWork
150 https://doi.org/10.1016/s0022-5347(05)66451-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015986636
151 rdf:type schema:CreativeWork
152 https://doi.org/10.1016/s0022-5347(05)66519-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029322735
153 rdf:type schema:CreativeWork
154 https://doi.org/10.1016/s0094-0143(05)70376-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014767971
155 rdf:type schema:CreativeWork
156 https://doi.org/10.1046/j.1442-2042.1999.00098.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1050520919
157 rdf:type schema:CreativeWork
158 https://doi.org/10.1056/nejm198710083171501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004570779
159 rdf:type schema:CreativeWork
160 https://doi.org/10.1056/nejmoa021659 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033436340
161 rdf:type schema:CreativeWork
162 https://doi.org/10.1056/nejmoa031918 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013014513
163 rdf:type schema:CreativeWork
164 https://doi.org/10.1093/annonc/mdl087 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051858254
165 rdf:type schema:CreativeWork
166 https://doi.org/10.1111/j.1442-2042.2005.01056.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1032114814
167 rdf:type schema:CreativeWork
168 https://doi.org/10.1111/j.1464-410x.2005.05800.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1050522621
169 rdf:type schema:CreativeWork
170 https://www.grid.ac/institutes/grid.415129.a schema:alternateName Fukui Red Cross Hospital
171 schema:name Department of Urology, Fukui Red Cross Hospital, Fukui, Japan
172 rdf:type schema:Organization
173 https://www.grid.ac/institutes/grid.9707.9 schema:alternateName Kanazawa University
174 schema:name Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, 920-8640, Kanazawa, Japan
175 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...